TELA Bio Inc
NASDAQ:TELA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
TELA Bio Inc
NASDAQ:TELA
|
33.3m USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.6T JPY |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
59.2B USD |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30.6B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
111.4B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.4B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.9B USD |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
41.5B CNY |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.1B CHF |
Loading...
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.7B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
TELA Bio Inc
Glance View
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 123 full-time employees. The company went IPO on 2019-11-08. The firm is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. The company offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), is used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. Its OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. Its subsidiary include TELA Bio Limited.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for TELA Bio Inc is -50.6%, which is above its 3-year median of -69.2%.
Over the last 3 years, TELA Bio Inc’s Net Margin has increased from -112.5% to -50.6%. During this period, it reached a low of -112.5% on Sep 30, 2022 and a high of -50.6% on Sep 30, 2025.
